Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Gross Profit (2019 - 2025)

Catalyst Pharmaceuticals' Gross Profit history spans 7 years, with the latest figure at $126.5 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 5.29% year-over-year to $126.5 million; the TTM value through Dec 2025 reached $501.7 million, up 18.64%, while the annual FY2025 figure was $501.7 million, 18.64% up from the prior year.
  • Gross Profit reached $126.5 million in Q4 2025 per CPRX's latest filing, up from $125.7 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $126.5 million in Q4 2025 to a low of $25.5 million in Q1 2021.
  • Average Gross Profit over 5 years is $78.5 million, with a median of $86.8 million recorded in 2023.
  • Peak YoY movement for Gross Profit: rose 2.15% in 2021, then soared 102.75% in 2023.
  • A 5-year view of Gross Profit shows it stood at $31.0 million in 2021, then skyrocketed by 60.08% to $49.6 million in 2022, then soared by 91.19% to $94.8 million in 2023, then rose by 26.82% to $120.2 million in 2024, then rose by 5.29% to $126.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Gross Profit are $126.5 million (Q4 2025), $125.7 million (Q3 2025), and $125.9 million (Q2 2025).